Mohini Ranganathan, MD

Yale University School of Medicine, New Haven, Connecticut; Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut

  • 5Articles
  • 46KReads
  • 2013–2025Active
  • 54Collaborators
  • 35Citations

About

Mohini Ranganathan, MD, is affiliated with Yale University School of Medicine and the Veterans Affairs Connecticut Healthcare System. Ranganathan has published extensively on addiction and major depressive disorder, focusing on topics such as personalized depression treatment using artificial intelligence, intravenous ketamine therapy for depression, and the clinical implications of medical marijuana. Additional work includes investigations into the endocannabinoid system's role in schizophrenia and adjunctive treatments for antipsychotic-induced hyperprolactinemia. Collaborations frequently involve co-authors Alexandra Anacleto, Angela A. Boggs, Anthony J. Gifuni, Avinash Hosanagar, and Barbara E. Peluse.

Publications

JCP
Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Clinical Decision Support System for Personalized Depression Treatment Selection and Management
Original Research

Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Clinical Decision Support System for Personalized Depression Treatment Selection and Management

August 27, 2025

This study provides preliminary evidence that longitudinal use of an AI-enabled clinical decision support system can improve outcomes in MDD.
, , , et al
JCP
Clinical Outcomes of IV Ketamine for Depression
Original Research

Clinical Outcomes of IV Ketamine for Depression

January 8, 2024

Short-term clinical trials found intravenous (IV) ketamine to be effective in reducing depressive symptoms. This study assessed longer-term outcomes of IV ketamine for depression and explored treatment and patient...
, , , et al
JCP
ASCP Corner

Medical Marijuana: What Physicians Need to Know

May 7, 2019

As of March 2019, "medical marijuana" has been approved in 33 states; however, these products are not FDA-regulated. This article summarizes the evidence for marijuana in psychiatric indications, as...
, ,
JCP
ASCP Corner

The Endocannabinoid System and Schizophrenia: Links to the Underlying Pathophysiology and to Novel Treatment Approaches

March 15, 2014

, , , et al
PCC
Letter to the Editor

Treatment of Hyperprolactinemia and Gynecomastia With Adjunctive Aripiprazole in 2 Men Receiving Long-Acting Injectable Antipsychotics

July 18, 2013

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe